Ekso Bionics Holdings Inc
F:23E2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Ekso Bionics Holdings Inc
F:23E2
|
US |
|
C
|
Clinuvel Pharmaceuticals Ltd
XBER:UR9
|
AU |
|
NCC Group PLC
LSE:NCC
|
UK |
|
Pepper Money Ltd
ASX:PPM
|
AU |
|
Root Inc
NASDAQ:ROOT
|
US |
|
Genting Singapore Ltd
F:36T
|
SG |
|
SeQuent Scientific Ltd
NSE:SEQUENT
|
IN |
|
C
|
Compagnie Generale des Etablissements Michelin SCA
F:MCH
|
FR |
|
C
|
CITIC Ltd
SWB:CPF
|
CN |
|
S
|
Standard Chartered PLC
F:STD
|
UK |
|
B
|
BK Holdings Co Ltd
KOSDAQ:050090
|
KR |
|
B
|
Boundless Bio Inc
NASDAQ:BOLD
|
US |
Wall St Price Targets
Price Targets Summary
Ekso Bionics Holdings Inc
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is Ekso Bionics Holdings Inc's stock price target?
Not Available
Ekso Bionics Holdings Inc does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Ekso Bionics Holdings Inc?
Projected CAGR
35%
Over the last 11 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 3 years is 35%.